About the role
Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) are epilepsy syndromes that have an onset early in life and are associated with learning disability (characterised by significant impairments in intellectual and adaptive functioning, with onset during the developmental period). Cannabidiol, used in combination with Clobazam, has been recommended as a treatment option for patients with LGS and DS.
Challenging behaviours are described as those ‘of such an intensity, frequency or duration as to threaten the quality of life and/or the physical safety of the individual or others and is likely to lead to responses that are restrictive, aversive or result in exclusion (Royal College of Psychiatrists, 2019).’ Challenging behaviours are prevalent among people with learning disability, and there are currently limited treatment options for patients where non-medication-based treatments (such as behavioural approaches) have proven insufficiently effective.
The aim of our study is to determine the effects of cannabidiol on challenging behaviour among people with LGS and DS who have been commenced on this medication for treatment of their seizures, as well as the acceptability of this treatment.
This is study involving a collaboration between University of Leicester (Associate Professor Samuel Tromans, co-lead), University of Plymouth (Professor Rohit Shankar, lead), University College London (Professor Angela Hassiotis), and Aston University (Professor Ian Maidment).
The post holder will also be centrally involved in the analysis of qualitative data relating to the evaluation, as well as preparation of interim and final evaluation reports, and corresponding journal articles for scientific publication.
About you
Not Specified